Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CALML3 | P27482 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 6/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6233760 | 1.00 | MAOA (0.40) | MAOAMAOBCALML3RIPK1NAAA | |
| SCHEMBL6233770 | 1.00 | MAOA (0.40) | MAOAMAOBCALML3RIPK1NAAA | |
| SCHEMBL6237165 | 0.90 | MAOA (0.43) | MAOAMAOBCALML3RIPK1 | |
| SCHEMBL6237162 | 0.90 | MAOA (0.43) | MAOAMAOBCALML3RIPK1 | |
| SCHEMBL6237168 | 0.90 | MAOA (0.43) | MAOAMAOBCALML3RIPK1 | |
| SCHEMBL6243258 | 0.89 | RIPK1 (0.37) | RIPK1NAAAPARP1 | |
| SCHEMBL6243259 | 0.89 | RIPK1 (0.37) | RIPK1NAAAPARP1 | |
| SCHEMBL6238906 | 0.88 | GRM2 (0.37) | RIPK1 | |
| SCHEMBL1976229 | 0.78 | RIPK1 (0.57) | RIPK1NAAA | |
| SCHEMBL19207870 | 0.78 | RIPK1 (0.57) | RIPK1NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050277630-A1 | Antibacterial agents | CHUPAK LOUIS S | 2005-12-15 | — | — | US | disclosed |
| EP-1594495-A1 | OXAZOLIDINONE DERIVATES N-SUBSTITUTED BY A TRICYCLIC RING, FOR USE AS ANTIBACTERIAL AGENTS | Warner-Lambert Company LLC (US) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004069245-A1 | OXAZOLIDINONE DERIVATES N-SUBSTITUTED BY A TRICYCLIC RING, FOR USE AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277630-A1 | Antibacterial agents | MRPL21, RPN2, FBL | MAOA 236/4885MAOB 221/4885CALML3 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.